Graft Versus Host Disease clinical trials at UC Davis

• Experimental Vedolizumab for Acute Graft Versus Host Disease (aGVHD) in Stem Cell Transplants

  open to eligible people ages 12 years and up

  The purpose of this study is to evaluate the efficacy of vedolizumab when added to background aGvHD prophylaxis regimen compared to placebo and background aGvHD prophylaxis regimen on intestinal aGvHD-free survival by Day +180 in participants who receive allo-HSCT as treatment for a hematologic malignancy or myeloproliferative disorder.

  Los Angeles, California and other locations

Last updated: July 17, 2020